We previously demonstrated that in vivo engagement of CD137, a member of TNF receptor superfamily, can delete allorective CD4
＋ T cells through the induction of activation-induced cell death (AICD) in chronic graft-versus-host disease (cGVHD) and subsequently reverse established cGVHD. In this study, we further showed that agonistic anti-CD137 mAb was highly effective in triggering AICD of donor CD8 ＋ T cells as well as donor CD4 ＋ T cells in the C57BL/6→unirradiated (C57BL/6 × DBA/2)F1 acute GVHD model. Our results suggest that strong allostimulation should facilitate AICD of both alloreactive CD4 ＋ and CD8 CD137 is a member of the TNF receptor family and functions as a costimulatory molecule for T cells (1) . Engagement of CD137 using anti-CD137 mAbs has been shown to effectively eradicate established tumors mainly through activation of CD8 ＋ T cells (1) . Paradoxically, however, anti-CD137 mAbs have strong immunosuppressive effects on a variety of autoimmune or inflammatory diseases that are believed to be mediated mainly by CD4 ＋ T cells (2) . A consensus on how stimulation of CD137 prevents disease has yet to emerge, but CD137 appears to be involved in the hyperactivation of T cells, causing them to acquire regulatory capacity or induce cell death (3).
In the DBA/2→unirradiated (C57BL/6 × DBA/2)F1 (BDF1) chronic graft-versus-host disease (cGVHD) model, anti-CD137 mAb is highly effective in inhibiting cGVHD by deleting donor CD4
＋ T cells which are required for breaking host B-cell tolerance (4) . In a more clinically relevant cGVHD model, anti-CD137 mAb reverses skin fibrosis, ulceration, and alopecia, a dominant feature of cGVHD, ultimately improving a general health condition (5). The reversal is associated with increased apoptosis of donor CD4 ＋ T cells. The Fas death pathway is required for activation-induced cell death (AICD) of alloreactive CD4 ＋ T cells.
In this study, we hypothesized that anti-CD137 mAb might induce AICD of alloreactive CD8
＋ T cells as well as CD4 ＋ T cells if they received strong allostimulation. We chose the C57BL/6→unirradiated BDF1 acute GVHD (aGVHD) model as a model system to test this hypothesis, since strong alloimmunity for donor CD4 ＋ and CD8 ＋ T cells occurs in this disease model. BDF1 mice received C57BL/6 T cells and anti-CD137 mAb (3H3) immediately after the cell transfer. FACS analysis showed that there was a marked increase in apoptosis of both splenic CD4 ＋ and CD8 ＋ T cells in anti-CD137-treated mice 5 days after the cell transfer (Fig. 1A) . A majority of donor CD4 ＋ and CD8 ＋ T cells expressed low levels of CD62L in both control Ig-and anti-CD137-treated mice ( 
ti-CD137 mAb, as compared with donor CD8
＋ T cells (Fig.   1 ). This result may indicate that donor CD4 ＋ T cells had a more rapid kinetics for their activation and subsequent AICD in response to anti-CD137 mAb.
A long-term observation demonstrated that control Ig-treated mice experienced severe loss of body weight and their mortality rate was high (70%), whereas anti-CD137-treated mice maintained normal body weight and stayed healthy until the termination of experiments (Fig. 2) . FACS analysis for splenocytes showed that administration of anti-CD137 mAb prevented severe lymphodepletion in the spleen, a parameter for aGVHD (Table I) . Anti-CD137-mediated inhibition of aGVHD was due to the deletion of donor CD4
＋ and CD8 ＋ T cells and a subsequent failure of donor cell engraftment (Table I ).
In two preclinical models of cGVHD, now it is clear that agonistic anti-CD137 mAb has the ability to delete pathogenic alloreactive CD4
＋ T cells and autoreactive B cells. However, there is evidence showing that agonistic anti-CD137 mAb can delete antigen-specific CD8 ＋ T cells as well as CD4 ＋ T cells in vivo (6, 7) . Earlier treatment with agonistic anti-CD137 mAb maintains elevated levels of TNF-α in lymphocytic choriomeningitis virus (LCMV)-infected mice, leading to Fas expression on activated CD8 ＋ T cells and this in turn results in Fas-mediated apoptosis (6) . Even though Fas-mediated death signal is not sufficient to delete LCMV antigen-specific CD8 ＋ T cells, STAT3 activation by signaling through CD137 in dendritic IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 6 December 2011 cells is required for their complete AICD (7) . In this study, we showed that agonistic anti-CD137 mAb could completely delete not only donor CD4 ＋ T cells but also CD8 ＋ T cells in the C57BL/6→BDF1 aGVHD model. As seen in cGVHD (4, 5) it is likely that engagement of CD137 provides strong costimulatory signaling leading to AICD for donor CD4 ＋ and CD8
＋ T cells that receive sustained allostimulation during the evolution of aGVHD. It remains to be elucidated whether other host hematopoietic and/or nonhematopoietic cells are needed for AICD of donor T cells by agonistic anti-CD137 mAb in GVHD.
